Skip to main content

Advertisement

SpringerLink
Log in

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 20 May 2011

Summary

LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. In biochemical and cellular assays, LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. With activities against both Tie2 and Eph receptors, LY2457546 possesses an activity profile that distinguishes it from multikinase inhibitors. When compared head to head with sunitinib, LY2457546 was more potent for inhibition of endothelial tube formation in an in vitro angiogenesis co-culture model with an intermittent treatment design. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 syngeneic rat mammary tumor model in both once and twice daily continuous dosing schedules and in mouse human tumor xenograft models of lung, colon, and prostate origin. Additionally, LY2457546 caused complete regression of well-established tumors in an acute myelogenous leukemia (AML) FLT3-ITD mutant xenograft tumor model. The observed efficacy that was displayed by LY2457546 in the AML FLT3-ITD mutant tumor model was superior to sunitinib when both were evaluated using equivalent doses normalized to in vivo inhibition of pKDR in mouse lung. LY2457546 was well tolerated in non-clinical toxicology studies conducted in rats and dogs. The majority of the toxicities observed were similar to those observed with other multi-targeted anti-angiogenic kinase inhibitors (MAKs) and included bone marrow hypocellularity, hair and skin depigmentation, cartilage dysplasia and lymphoid organ degeneration and necrosis. Thus, the unique spectrum of target activity, potent in vivo anti-tumor efficacy in a variety of rodent and human solid tumor models, exquisite potency against a clinically relevant model of AML, and non-clinical safety profile justify the advancement of LY2457546 into clinical testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

    Article  PubMed  CAS  Google Scholar 

  2. Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109:227–241

    Article  PubMed  CAS  Google Scholar 

  3. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    PubMed  CAS  Google Scholar 

  4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

  5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 8:299–309

    Article  PubMed  CAS  Google Scholar 

  6. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248

    Article  PubMed  CAS  Google Scholar 

  7. Barda DA, Burkholder TP, Clayton JR, Hao Y, Henry JR, Knobeloch JM, McLean JA, Mendel D, Rempala ME, Wang ZQ, Yip YY, Zhong B (2010) U.S. Patent 7 666 879

  8. Okram B, Nagle A, Adrian FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray N (2006) A general strategy for creating “inactive-conformation” Abl inhibitors. Chem Biol 13:779–786

    Article  PubMed  CAS  Google Scholar 

  9. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Sructural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938–1942

    Article  PubMed  CAS  Google Scholar 

  10. Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697:17–27

    PubMed  CAS  Google Scholar 

  11. Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M (2005) Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg Med Chem Lett 15:3519–3523

    Article  PubMed  CAS  Google Scholar 

  12. Jung FH, Pasquet G, Lambert-van der Brempt C, Lohman JM, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 49:955–970

    Article  PubMed  CAS  Google Scholar 

  13. Huss KL, Blonigen PE, Campbell RM (2007) Development of a TranscreenerTM kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen 12:578–584

    Article  PubMed  CAS  Google Scholar 

  14. Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, Smallwood JE, Christe ME, Chatterjee A, Goodson T Jr, Vlahos CJ, Matter WF, Bloem LJ (2005) Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 280:19298–19305

    Article  PubMed  CAS  Google Scholar 

  15. Hasumi Y, Babaa M, Ajimab R, Hasumi H, Valeraa VA, Kleina ME, Hainesc DC, Merinod MJ, Honga S-B, Yamaguchib TP, Schmidt LS, Linehana WM (2009) Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 PNAS, 106: 18722–18727

  16. Chen Y, Wei T, Yan L, Lawrence L, Qian H-R, Burkholder TP, Starling JJ, Yingling JM, Shou J (2008) Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. BMC Genomics 9:264

    Article  PubMed  Google Scholar 

  17. Abu-Ehuler FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111:190–195

    Article  Google Scholar 

  18. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000) (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14(4):675–683

    Article  PubMed  CAS  Google Scholar 

  19. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89–94

    Article  PubMed  CAS  Google Scholar 

  20. Obermann EC, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A (2010) Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol 89:663–669

    Article  PubMed  CAS  Google Scholar 

  21. Hall AP, Westwood FR, Wadsworth PF (2006) Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34(2):131–4

    Article  PubMed  CAS  Google Scholar 

  22. Sutent (Sunitinib Malate) (2006) Pharmacology review, NDA Application No.: 021938 & 021968, Pfizer Inc

  23. Nexavar (Sorafenib Tosylate): Pharmacology Review, NDA Application No.: 021923, 2005. Bayer Pharmaceuticals Corporation

  24. Avastin (Bevacizumab): Pharmacology Review, BLA Application No.: 125085, 2004. Genetech, Inc

  25. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD (2003) Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307(2):476–80

    Article  PubMed  CAS  Google Scholar 

  26. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491–500

    Article  PubMed  CAS  Google Scholar 

  27. Robert C, Spatz A, Faivre S, Armand JP, Raymond E (2003) Tyrosine kinase inhibition and grey hair. Lancet 361(9362):1056

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Steve Hatch, Baohui Zhao, Julie A. Stewart, Jason R. Manro, Andrew R. Capen, Lysiane Huber, Phil Schwier, Lisa Kays, Spring Weir, James E. McGee, Jeffrey K. Smallwood, Robert B. Peery, Jianyong Shou, Joan H. Carter, Karen S. Britt, Bryan Dirk Anderson, Robert M. Campbell, and Aimee K. Bence for helpful discussions and for conducting experiments and data analyses in support of these studies.

Conflict of interest

All Lilly employees are employed by and hold stocks in Eli Lilly and Company, which owns LY2457546.

Author information

Authors and Affiliations

  1. Discovery Chemistry Research and Technology, Eli Lilly and Company, Indianapolis, IN, USA

    Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala, James R. Henry, John M. Knobeloch, David Mendel, Johnathan A. McLean, Yan Hao & David A. Barda

  2. Oncology Drug Discovery, Eli Lilly and Company, Indianapolis, IN, USA

    Eileen L. Considine, Mark T. Uhlik, Yuefeng Chen, Liandong Ma & James J. Starling

  3. Lead Generation/Lead Optimization Biology, Eli Lilly and Company, Indianapolis, IN, USA

    Laura J. Bloem

  4. Non-clinical Toxicology, Eli Lilly and Company, Indianapolis, IN, USA

    Jacqueline K. Akunda

  5. Drug Disposition, Eli Lilly and Company, Indianapolis, IN, USA

    Denis J. McCann

  6. Preformulation, Eli Lilly and Company, Indianapolis, IN, USA

    Manuel Sanchez-Felix

  7. Structural Biology, Eli Lilly and Company, Indianapolis, IN, USA

    David K. Clawson

  8. Early Oncology Clinical Investigation, Eli Lilly and Company, Indianapolis, IN, USA

    Michael M. Lahn

Authors
  1. Timothy P. Burkholder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua R. Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark E. Rempala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James R. Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John M. Knobeloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Mendel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johnathan A. McLean
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David A. Barda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eileen L. Considine
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mark T. Uhlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuefeng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Liandong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Laura J. Bloem
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jacqueline K. Akunda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Denis J. McCann
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Manuel Sanchez-Felix
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. David K. Clawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Michael M. Lahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. James J. Starling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Timothy P. Burkholder or James J. Starling.

Additional information

Funding

The study was sponsored by Eli Lilly and Company.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burkholder, T.P., Clayton, J.R., Rempala, M.E. et al. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model. Invest New Drugs 30, 936–949 (2012). https://doi.org/10.1007/s10637-011-9640-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9640-6

Keywords

Search

Navigation